Insulin vs Glucagon: A Technical Pros and Cons Analysis
Abstract: This technical analysis contrasts insulin and glucagon as foundational peptide therapeutics. Insulin excels in glycemic control via cellular glucose uptake, yet poses hypoglycemia risks and injection-site lipodystrophy. Glucagon’s primary advantage is rapid counter-regulation of severe hypoglycemia, though its short half-life limits basal utility. Market trends show a surge in once-weekly insulin analogs (e.g., icodec) and stable glucagon nasal powders. Brand comparisons (Novo Nordisk vs. Eli Lilly) highlight differences in purity, stability, and delivery devices. Regulatory certifications (FDA, EMA) are critical for quality assurance. Selection criteria prioritize pharmacokinetics, immunogenicity, and cold-chain logistics. Industry data projects a $45B peptide market by 2030, driven by diabetes and obesity indications.